Patients suffering from hypertension as a result of elevated blood pressure will see few new drugs on the market as very few novel therapies are set to become available through to 2018, according to a new report by Decision Resources.

According to the report, in addition to extensive generic erosion, only Novartis, Pharmacopeia and Cytos Biotechnology have novel agents in mid- to late-stage development for hypertension.

The most promising new treatment, Gilead’s darusentan, was positioned to be the next emerging therapy with a novel mechanism until failure to reach its primary endpoint in the recent DORADO-AC Phase III clinical trial resulted in further development being terminated.

Decision Resources analyst Caroline Gates said that in terms of novel emerging therapies, focus has now shifted to the separate ongoing clinical trials of Novartis, Pharmacopeia and Cytos’s new drugs.

“In particular, with regard to Novartis’s LCZ-696, interviewed experts believe that physicians will be very enthusiastic about this drug if it demonstrates the ability to lower blood pressure to the same extent as Bristol-Myers Squibb‘s Vanlev but without a similarly high incidence of angioedema,” Gates said.

The Pharmacor 2010 findings reveal that the hypertension drug market will decrease modestly by 1.5% annually to 2013. Thereafter, annual decline will slow to 1% to 2018 in the US, France, Germany, Italy, Spain, the UK and Japan.